CULLINAN ONCOLOGY LLC
NASDAQ: CGEM (Cullinan Therapeutics, Inc.)
最近更新时间: 4小时之前8.31
-0.48 (-5.46%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Cullinan Therapeutics, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.38 |
|
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 4.93% |
| 机构持股比例 | 117.51% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 35.00 (Morgan Stanley, 321.18%) | 购买 |
| 中 | 34.00 (309.15%) | |
| 低 | 33.00 (HC Wainwright & Co., 297.11%) | 购买 |
| 平均值 | 34.00 (309.15%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 8.16 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 16 Apr 2025 | 33.00 (297.11%) | 购买 | 7.61 |
| 28 Feb 2025 | 33.00 (297.11%) | 购买 | 8.49 | |
| Morgan Stanley | 07 Mar 2025 | 35.00 (321.18%) | 购买 | 8.71 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合